|Bid||119.79 x 1100|
|Ask||120.60 x 1200|
|Day's range||118.16 - 121.11|
|52-week range||62.57 - 151.51|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||152.91|
Celebrations may be in order for Biohaven Pharmaceutical Holding Company Ltd. ( NYSE:BHVN ) shareholders, with the...
Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.
Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.